SEARCH
Aim is to move above 20% EBITDA, says GSK Pharma
CNBC-TV18
2019-08-19
Views
8
Description
Share / Embed
Download This Video
Report
From the Motilal Oswal 15th Investor Conference, Annaswamy Vaidheesh, vice president P-South Asia and India MD of Glaxosmithkline Pharmaceuticals shared his views and outlook.
Show more
Share This Video
facebook
google
twitter
linkedin
email
Video Link
Embed Video
<iframe width="600" height="350" src="https://dailytv.net//embed/x7gn9wh" frameborder="0" allowfullscreen></iframe>
Preview Player
Download
Report form
Reason
Your Email address
Submit
RELATED VIDEOS
08:26
Focussing on brands with higher margin & growth prospects, says GSK Pharma
10:43
PM Modi's demonetisation move was aimed at political gains, says BSP Chief Mayawati
02:41
Expect 12-13% EBITDA Growth In FY19, Says Galaxy Surfactants
09:09
See incremental EBITDA of Rs 100-120 crore on merger of Tata Chemical consumer biz, says Rakesh Sony of Tata Global Beverages
06:52
Expect 30% growth on topline & 20% EBITDA growth in FY20, says IRB Infra
04:20
Expect EBITDA margins to be in the late teens in next two-three years, says Radico Khaitan
01:46
GSK says tests hint Covid-19 drug fights Omicron
00:36
Move the Notting Hill Carnival from West London's narrow streets if Met says it's too dangerous, Chris Philip says
04:26
TikTok Responds To India Ban, Says Invited To Submit Clarifications; China Says Move Discriminatory
02:40
Not a single bullet fired despite border dispute with China says Modi and Trump says isolating Qatar is a good move
06:33
Kavanaugh says 'NO ONE IS ABOVE THE LAW' But won't say if Donald Trump can pardon himself. #DonaldTrump #CNN #News #Kavanaugh
00:18
Pharma Douche Martin Shkreli Says 'I Would've Raised Prices Higher'